Annals of Hematology最新文献_第2页

Identification of molecular clusters and a risk prognosis model for diffuse large B-cell lymphoma based on lactate metabolism-related genes.

IF 3 3区医学

Annals of Hematology Pub Date : 2025-04-05 DOI: 10.1007/s00277-025-06321-1

Jie Zhang, Ting Gao, Shan Chen, Shuang Wu, Yong Mao, Dongyan Cai, Tingxun Lu

{"title":"Identification of molecular clusters and a risk prognosis model for diffuse large B-cell lymphoma based on lactate metabolism-related genes.","authors":"Jie Zhang, Ting Gao, Shan Chen, Shuang Wu, Yong Mao, Dongyan Cai, Tingxun Lu","doi":"10.1007/s00277-025-06321-1","DOIUrl":"https://doi.org/10.1007/s00277-025-06321-1","url":null,"abstract":"Diffuse large B-cell lymphoma (DLBCL) is a leading cause of morbidity and mortality among lymphomas in adults, with tumor cells undergoing metabolic reprogramming linked to the immune microenvironment. This study explored the relationship between lactate metabolism-related genes (LMRGs), DLBCL prognosis, and immune microenvironment interactions. Publicly available datasets (GSE10846 and GSE87371) were analyzed, with LMRGs identified using Cox regression and LASSO regression. A risk prognosis model comprising five LMRGs was developed, showing that high-risk patients had worse outcomes due to adverse clinical features, aggressive immune microenvironments, and poor treatment responses. A nomogram combining the model with clinical data predicted 1-, 3-, and 5-year survival. Single-cell RNA sequencing indicated that high LMRG risk scores in B cells may promote immunosuppression via the MIF-CD74/CXCR4 pathway. Functional validation revealed that SDHA knockdown reduced DLBCL cell proliferation in U2932 and KIS-1 cell lines. This LMRG-based model serves as a valuable tool for predicting survival, immune landscape, and clinical risk stratification in DLBCL patients, while also highlighting the crucial role of lactate metabolism in DLBCL pathogenesis. Furthermore, these findings underscore the potential of LMRGs risk scores to guide personalized therapies and improve treatment outcomes.","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143787583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

CXCL9 and IL-18: potential biomarkers for efficacy evaluation in refractory hemophagocytic lymphohistiocytosis treated with RED (ruxolitinib, emapalumab and dexamethasone).

IF 3 3区医学

Annals of Hematology Pub Date : 2025-04-05 DOI: 10.1007/s00277-025-06336-8

Xuan Lan, Na Wei, Jingshi Wang, Zhao Wang

{"title":"CXCL9 and IL-18: potential biomarkers for efficacy evaluation in refractory hemophagocytic lymphohistiocytosis treated with RED (ruxolitinib, emapalumab and dexamethasone).","authors":"Xuan Lan, Na Wei, Jingshi Wang, Zhao Wang","doi":"10.1007/s00277-025-06336-8","DOIUrl":"https://doi.org/10.1007/s00277-025-06336-8","url":null,"abstract":"Hemophagocytic lymphohistiocytosis (HLH) is a severe inflammatory disorder characterized by excessive cytokine release. More than 30% of HLH cases are refractory to frontline therapy. Unfortunately, there is no universally accepted second-line regimen, and about 30% of patients fail to respond to current salvage treatments. Moreover, evidence guiding alternative therapies and the optimal timing for switching to new treatments in refractory patients is limited. This study retrospectively analyzed the efficacy and safety of the RED regimen (ruxolitinib, emapalumab, and dexamethasone) in 15 refractory HLH patients who had failed at least two previous salvage therapies. Overall, eight (53.3%) patients achieved partial remission, and four of those eight proceeded to hematopoietic stem cell transplantation (HSCT). Notably, pre-RED levels of C-X-C motif chemokine 9 (CXCL9) and interleukin-18 (IL-18) were significantly higher in patients who later responded to RED, suggesting that these biomarkers may predict a better response. We also observed that, for eight partial-remission patients, hemoglobin, fibrinogen, aspartate aminotransferase, calcium, and CXCL9 levels tracked well with early therapeutic responses (one to two weeks). No grade 3 or higher adverse effects were linked to the RED regimen. This comprehensive investigation of the RED approach in HLH, although small in sample size, supports the possibility that RED can serve as an effective and relatively safe salvage therapy for refractory HLH.","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143787580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy of venetoclax combined with homoharringtonine and cytarabine for younger adults with newly diagnosed AML.

IF 3 3区医学

Annals of Hematology Pub Date : 2025-04-04 DOI: 10.1007/s00277-025-06250-z

Bao-Quan Song, Xin Kong, Yin Liu, Yan Pu, Jian Zhang, De-Pei Wu, Hui-Ying Qiu

{"title":"Efficacy of venetoclax combined with homoharringtonine and cytarabine for younger adults with newly diagnosed AML.","authors":"Bao-Quan Song, Xin Kong, Yin Liu, Yan Pu, Jian Zhang, De-Pei Wu, Hui-Ying Qiu","doi":"10.1007/s00277-025-06250-z","DOIUrl":"https://doi.org/10.1007/s00277-025-06250-z","url":null,"abstract":"Venetoclax (VEN)--based induction therapy has demonstrated considerable promise in treating acute myeloid leukemia (AML); however, the optimal VEN-based combination therapy remains to be established. This study evaluated the efficacy and safety of the venetoclax-homoharringtonine-cytarabine (VHA) regimen in patients with newly diagnosed (ND) AML. A retrospective analysis was conducted on 55 patients treated with the VHA regimen. The overall response rate (ORR) was 92.7% (51/55, 95% CI 82%-98%), and the composite complete remission (CRc) rate was 87.3% (48/55, 95% CI 76%-95%). Among the 48 patients who achieved CRc, 91.7% (44/48, 95% CI 67%-90%) achieved complete remission (CR), and 85.4% (41/48, 95% CI 72%-94%) reached measurable residual disease (MRD)-negative CR. In the adverse-risk group, ORR and CRc were 95% (19/20, 95% CI 75%-100%) and 75% (15/20, 95% CI 51%-91%), respectively. The most common grade 3-4 adverse events were febrile neutropenia (32.7%), pneumonia (16.3%), and sepsis (9.1%). Median overall survival (OS) was 26 months, while event-free survival (EFS) was not reached. One-year OS was 83%, and one-year EFS was 82%. These preliminary data suggest that the VHA regimen achieves a very high rate of CR and low toxicity, particularly for adverse-risk AML patients.","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143778893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A case series of B-Lymphoblastic lymphoma with C-MYC rearrangement in children: diagnostic and therapeutic challenges. 儿童 C-MYC 重排 B 淋巴细胞淋巴瘤病例系列：诊断和治疗难题。

IF 3 3区医学

Annals of Hematology Pub Date : 2025-04-04 DOI: 10.1007/s00277-025-06330-0

Xueliang Yang, Yanlong Duan, Chunju Zhou, Ningning Zhang, Xueqing Bai, Ling Jin, Shuang Huang, Meng Zhang

引用次数: 0

An unexpected find of multifocal extranodal marginal zone lymphoma.

IF 3 3区医学

Annals of Hematology Pub Date : 2025-04-03 DOI: 10.1007/s00277-025-06283-4

Glenn Van den Bosch, M Develter, J Willemse, J Boes, K Somers, U Douven

引用次数: 0

Radiotherapy alone with curative intent in a case of limited-stage extranodal NK/T-cell lymphoma nasal type: a case report and review of the literature.

IF 3 3区医学

Annals of Hematology Pub Date : 2025-04-03 DOI: 10.1007/s00277-025-06260-x

Biancamaria Mandelli, Donatella Caivano, Antonella Fontana, Natalia Cenfra, Sergio Mecarocci, Maristella Marrocco, David Fanciullo, Roberta Mazzarella, Martina Lorenzon, Giada Pacitto, Alessandro Pulsoni

{"title":"Radiotherapy alone with curative intent in a case of limited-stage extranodal NK/T-cell lymphoma nasal type: a case report and review of the literature.","authors":"Biancamaria Mandelli, Donatella Caivano, Antonella Fontana, Natalia Cenfra, Sergio Mecarocci, Maristella Marrocco, David Fanciullo, Roberta Mazzarella, Martina Lorenzon, Giada Pacitto, Alessandro Pulsoni","doi":"10.1007/s00277-025-06260-x","DOIUrl":"https://doi.org/10.1007/s00277-025-06260-x","url":null,"abstract":"Extranodal NK/T-cell lymphoma, nasal type (ENKTCL-NT), is an aggressive malignancy primarily affecting the sinonasal region, with a strong association with Epstein-Barr virus (EBV) infection. The disease is significantly more prevalent in Asian and Latin American populations. Diagnosis is particularly challenging in nonendemic regions. We present the case of a 78-year-old male with a one-year history of nasal lesions, later diagnosed with ENKTCL-NT. The patient was treated with curative-intent radiotherapy, achieving a complete clinical response. Radiation therapy, particularly utilizing advanced techniques such as Volumetric Modulated Arc Therapy (VMAT), resulted in favorable outcomes with minimal toxicity. This case emphasizes the importance of early diagnosis, accurate staging, and personalized radiotherapy in the management of ENKTCL-NT. Ongoing research into the molecular pathogenesis, treatment strategies, and prognostic factors is crucial for improving outcomes, particularly in advanced-stage disease.","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143771116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Navigating the peginterferon Alfa-2a shortage: practical guidance on transitioning patients to ropeginterferon alfa-2b.

IF 3 3区医学

Annals of Hematology Pub Date : 2025-04-03 DOI: 10.1007/s00277-025-06331-z

Ruben Mesa, Abdulraheem Yacoub, Tsewang Tashi, Wanxing Chai-Ho, Chang Ho Yoon, John Mascarenhas

引用次数: 0

Real-world data of siltuximab for Chinese patients with iMCD: combination with BCD regimen as a potential approach for severe cases.

IF 3 3区医学

Annals of Hematology Pub Date : 2025-04-03 DOI: 10.1007/s00277-025-06329-7

Si-Yuan Li, Yu-Han Gao, Yue Dang, Long Chang, Kai-Ni Shen, Hua-Cong Cai, Dan-Qing Zhao, Chong Wei, Jun Feng, Lu Zhang, Jian Li

{"title":"Real-world data of siltuximab for Chinese patients with iMCD: combination with BCD regimen as a potential approach for severe cases.","authors":"Si-Yuan Li, Yu-Han Gao, Yue Dang, Long Chang, Kai-Ni Shen, Hua-Cong Cai, Dan-Qing Zhao, Chong Wei, Jun Feng, Lu Zhang, Jian Li","doi":"10.1007/s00277-025-06329-7","DOIUrl":"https://doi.org/10.1007/s00277-025-06329-7","url":null,"abstract":"Idiopathic multicentric Castleman disease (iMCD) is a rare disease characterized by polyclonal lymphoproliferation and systemic inflammation. Siltuximab, targeting interleukin-6 (IL-6), has been recommended as the first-line therapy for iMCD. However, substantial real-world data from China were still lacking, and treatment for patients with severe iMCD remained challenging. This single-center retrospective study investigated the real-world efficacy and safety of siltuximab-based therapy in 43 consecutive patients with iMCD in China from July 2022 to March 2024. The overall response rate (including symptomatic and biochemical response) was 59% at week 3 and increased to 91% at week 12, with complete and partial response rates of 54% and 37%, respectively. Patients who received siltuximab as a first-line treatment exhibited better treatment response (OR = 0·040, 95% CI, 0·004 - 0·390, p = 0·006). Inflammatory markers (such as interleukin-6 and high-sensitivity C-reactive protein [hsCRP]) and pathologic types showed no predictive role in the treatment responses. Eighteen patients, who were all classified as severe iMCD, received combined therapy of siltuximab and BCD regimen (bortezomib, cyclophosphamide and dexamethasone). Of them, the overall response rate was 50% at week 3, which increased to 100% at week 12. Our findings reinforced the existing evidence on the efficacy and safety of siltuximab and highlighted the potential benefits of combining siltuximab with BCD regimen in severe iMCD patients.","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143771119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Successful sequential application of CAR T-cell-therapies in relapsed refractory multiple myeloma.

IF 3 3区医学

Annals of Hematology Pub Date : 2025-04-03 DOI: 10.1007/s00277-025-06340-y

Paul Mobascher, Monika Engelhardt, Ralph Wäsch

引用次数: 0

Building a new score system for the diagnosis and differential diagnosis of typical CLL/SLL, atypical CLL/SLL, and MCL based on the flow cytometry immunophenotyping.

IF 3 3区医学

Annals of Hematology Pub Date : 2025-04-01 DOI: 10.1007/s00277-025-06231-2

Emile Niyonizeye, Xiaoqian Wang, Dongyao Yan, Seidu A Richard, Huijun Ren, Liyan Fu, Yaoyao Chen, Xiaogeng Yuan, Baohong Yue

{"title":"Building a new score system for the diagnosis and differential diagnosis of typical CLL/SLL, atypical CLL/SLL, and MCL based on the flow cytometry immunophenotyping.","authors":"Emile Niyonizeye, Xiaoqian Wang, Dongyao Yan, Seidu A Richard, Huijun Ren, Liyan Fu, Yaoyao Chen, Xiaogeng Yuan, Baohong Yue","doi":"10.1007/s00277-025-06231-2","DOIUrl":"https://doi.org/10.1007/s00277-025-06231-2","url":null,"abstract":"The diagnosis and differential diagnosis of typical lymphocytic leukaemia (CLL)/Small lymphocytic lymphoma(SLL) especially atypical CLL/SLL (aCLL/SLL), and mantle cell lymphoma (MCL) remains highly challenging. Thus, we evaluated the accuracy of the combination of the Moreau score system (MSS) indicators (markers), with three new indicators CD19/CD20 ratio, CD200, and CD43 in diagnosis and differential diagnosis of typical CLL/SLL, atypical CLL/SLL, and MCL. We retrospectively retrieved data from peripheral blood, bone marrow, and lymph nodes of 120 patients comprising 64 typical CLL, 10 atypical CLL, and 46 MCL from March 2020 to September 2023 at the First Affiliated Hospital of Zhengzhou University. Multiparametric evaluation flow cytometry and immunophenotype were obtained via a B-cell panel and pathological reports were carried out. We observe that the new score system (NSS) and the MSS had the same specificity. However, the NSS demonstrated to have superior sensitivity compared to MSS. Adding three new markers CD19/CD20, CD200, and CD43 is accountable for the superior sensitivity in our NSS. Also, a combination of markers such as CD19, CD20, CD5, CD23, CD79b, FMC7, SmIg, CD22, CD43, CD200, the ratio CD19/CD20 may be a potential differentiating modality for typical CLL/SLL, atypical CLL/SLL, and MCL. Adding the CD19/CD20 ratio, CD43, and CD200 indicators to the MSS indicators could be potentially accurate diagnostic and differential diagnosis modality for typical CLL/SLL, atypical CLL/SLL, and MCL.","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143750832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0